QC managers and lab directors in pharma, biotech, food and beverage, and manufacturing face the same fundamental challenge every day: test results must be trusted. Not just internally trusted, but audit-ready, defensible, and fully traceable from sample receipt to final analytical report.

Understanding what quality control in a laboratory actually requires — from the regulatory framework to the software that supports it — is the foundation of a compliant, high-performing lab operation.

What Is Quality Control in a Laboratory?

Quality control in a laboratory refers to the technical activities and documented procedures used to verify that analytical methods produce accurate, precise, and reproducible results. These activities confirm that test data is valid before any batch release, regulatory submission, or product disposition decision is made.

Laboratory QC encompasses the management of reference standards, reagent qualification, instrument calibration, analyst qualification, out-of-specification (OOS) investigation protocols, and method validation. Each component serves a specific function within the broader laboratory quality management system.

The FDA's Guide to Inspections of Pharmaceutical Quality Control Laboratories describes the QC laboratory as one of the most important functions in pharmaceutical production and control, noting that a significant portion of cGMP regulations under 21 CFR Part 211 directly pertain to it.

QC vs. QA in the Laboratory Context

Quality control and quality assurance are related but distinct. Quality assurance (QA) is proactive: it covers the policies, systems, and preventive processes designed to ensure compliance before problems occur. QC is reactive and technical: it involves actual testing, measurement, and inspection to confirm that results meet predefined specifications.

In a regulated lab, QA designs the system. QC verifies that the system works. Both functions must operate together, and both must be supported by validated systems with complete audit trails.

The Regulatory Framework for Laboratory Quality Control

FDA 21 CFR Part 211 (Subpart I: Laboratory Controls)

For pharmaceutical manufacturers, the primary regulatory basis for laboratory QC is Subpart I of 21 CFR Part 211, which covers laboratory controls for drug product manufacturing. Key requirements include:

• 21 CFR 211.160: All testing instruments must be calibrated against standards with known accuracy and precision. Accuracy, sensitivity, specificity, and reproducibility of test methods must be established and documented.
• 21 CFR 211.165: Testing requirements for finished products, including identity, strength, quality, purity, and release against approved specifications for every batch before distribution.
• 21 CFR 211.166: Stability testing programs must be designed to cover the labeled shelf life and storage conditions of each drug product.
• 21 CFR 211.167: Special testing requirements for specific product types, including sterility testing and pyrogen testing for injectable and ophthalmic preparations.
• 21 CFR 211.192: All laboratory records must be reviewed by the quality control unit before batch release, with any unexplained discrepancy requiring a formal investigation.

ISO 13485 Clause 7.6 (Medical Device Monitoring and Measurement Equipment)

For medical device manufacturers, ISO 13485:2016 Clause 7.6 requires that monitoring and measuring equipment be calibrated or verified at specified intervals, adjusted as necessary, identified with calibration status, and protected from adjustments that would invalidate the measurement result. Calibration records must be maintained and available for review.

ISO 17025 (Testing and Calibration Laboratories)

For contract testing laboratories and quality control labs seeking formal accreditation, ISO/IEC 17025:2017 provides the international standard for technical competence. ISO 17025 covers management requirements (document control, control of records, internal audits, management review) and technical requirements (personnel competence, equipment, measurement traceability, test and calibration methods, and results reporting). FDA-regulated companies that use ISO 17025-accredited laboratories can reference that accreditation as part of their supplier qualification documentation.

FDA Data Integrity Guidance

The FDA's series of data integrity guidance documents, including the 2018 guidance on data integrity and cGMP compliance, establishes that all laboratory data, including raw chromatographic files, weighing records, instrument logs, and audit trails, must meet ALCOA+ requirements: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. For laboratory computer systems, this means electronic records must comply with 21 CFR Part 11.

Core Elements of Laboratory Quality Control

Method Validation

Before an analytical procedure can be used for regulated testing, it must be validated. Method validation demonstrates that the procedure is suitable for its intended purpose by establishing and documenting its specificity, linearity, range, accuracy, precision, detection limit, quantitation limit, and robustness, as required by ICH Q2(R2) for pharmaceutical analytical methods.

Method validation records are controlled documents subject to change control. When a validated method must be modified, a partial revalidation must be performed and documented to demonstrate that the change does not invalidate the method's performance characteristics.

Reference Standards Management

Reference standards used in QC testing must be characterized, qualified, and stored under documented conditions. Primary reference standards (pharmacopeial standards or equivalent) must be obtained from a recognized source. Secondary or working standards must be qualified against primary standards with documented traceability.

Expiry dates, storage conditions, and usage records for all reference standards must be maintained, and expired standards must be immediately removed from use. In a compliant system, reference standard records are integrated with the testing workflow so that expired or unqualified standards cannot be used in a test without generating a system flag.

Instrument Qualification and Calibration

Every instrument used in QC testing must be qualified before use and maintained in a qualified state throughout its operational life. Qualification follows a four-stage model: Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ), with the level of qualification proportionate to the instrument's risk and criticality.

Calibration is an ongoing requirement for all measurement instruments. Calibration schedules must be documented, calibration must be performed against standards traceable to national or international measurement standards, and calibration records must be retained for the life of the instrument plus the applicable retention period for regulated records.

Out-of-calibration findings must be documented, assessed for impact on results generated since the last successful calibration, and investigated through a formal Deviation CAPA process if the calibration failure affected any released product or regulatory submission.

Analyst Qualification

Analysts performing regulated testing must be qualified for the specific methods they perform. Qualification records must document initial training, method-specific qualification testing (typically through spiked sample analysis or parallel testing against a qualified analyst), and ongoing competency assessments.

Analyst qualification status must be current at the time any test result is recorded. Systems that tie analyst qualification records directly to test documentation — preventing an unqualified analyst from completing a regulated test record — provide stronger compliance controls than those relying on procedural safeguards alone.

Out-of-Specification (OOS) Investigation

An OOS result is any analytical result that falls outside the established acceptance criteria specified in drug product specifications, USP/NF monographs, or the manufacturer's established release limits. Under FDA guidance, every OOS result must be investigated through a two-phase process:

Phase I: Laboratory Investigation. The laboratory immediately investigates whether the OOS result can be attributed to an assignable laboratory error. This phase includes reviewing the analytical run for computational errors, assessing whether the instrument was functioning correctly, evaluating analyst technique, and checking reference standard and reagent status. If a confirmed laboratory error is identified and documented, the result may be invalidated and the sample re-analyzed.

Phase II: Full Investigation. If Phase I finds no assignable laboratory error, a full investigation expands to the manufacturing process. This phase involves the Quality unit, production, and potentially the original manufacturing batch record review. Additional testing (including retained samples and stability samples if applicable) may be conducted under a documented protocol.

OOS investigations must be completed before batch disposition. Batches cannot be released with an open, unresolved OOS investigation. The investigation record must document the root cause conclusion, any corrective actions taken, and the final batch disposition decision with its scientific and regulatory justification.

Cloudtheapp's Out of Specification application provides a structured, validated workflow for managing OOS investigations from initial flagging through Phase I and Phase II investigation, corrective action linkage, and final disposition, with full audit trail capture at every step.

Laboratory Deviation Management

Deviations in the laboratory context include departures from approved test procedures, unexpected instrument behavior, sample handling errors, and any other departure from the planned conduct of a test or study. Every deviation must be documented through a formal deviation report, assessed for its impact on the validity of associated results, and reviewed and closed by the quality unit before the affected results are used for any regulatory purpose.

Recurring deviations, or deviations that reveal a systemic gap in procedures, equipment, or analyst qualification, should generate a Deviation CAPA to address the root cause and prevent recurrence.

Stability Testing

For pharmaceutical manufacturers, stability testing is a defined program that demonstrates a drug product continues to meet its specifications throughout its labeled shelf life under specified storage conditions. Stability studies must follow ICH Q1A(R2) guidelines and be supported by a validated stability program with a documented protocol, sampling schedule, and time-point testing assignments.

Laboratory QC systems that manage stability testing must track sample storage locations, issue testing alerts at scheduled time points, document results against stability acceptance criteria, and flag out-of-trend (OOT) results for investigation. Stability results are a core element of ANDA submissions, NDA post-approval supplements, and regulatory shelf life extensions.

Laboratory Records: What FDA Investigators Examine

Laboratory records in FDA-regulated environments are not just internal documentation. They are the primary evidence base for inspection findings and regulatory submissions. Investigators routinely examine the following:

Raw data. In computerized systems, raw data includes the original instrument output files — chromatograms, spectral data, weighing records — before any processing or reduction. FDA investigators have issued warning letters for companies that could not produce raw data to support submitted results, or where raw data showed discrepancies with reported results.

Analytical worksheets and run documentation. Every analytical run must be documented with the date, analyst identification, instrument identification, reagent and standard lot numbers and expiry dates, and the sequence of calculations used to derive reported results.

Audit trails. For computerized laboratory systems, the complete electronic audit trail must capture all access, entries, modifications, and deletions to analytical records, with user attribution and timestamps. The audit trail must be retained for the same period as the associated laboratory records.

OOS and deviation records. The history of all OOS results and laboratory deviations associated with a batch or stability program must be available for inspection, with documented investigation outcomes.

Analyst qualification and training records. Evidence that each analyst who performed testing was qualified for the applicable methods at the time of testing must be maintained and cross-referenceable to the analytical records.

How Laboratory Quality Control Software Closes These Gaps

Purpose-built laboratory quality control software integrates all of the above elements into a single validated environment, eliminating the manual reconciliation, version control failures, and data integrity gaps that paper-based and general-purpose systems cannot address.

Cloudtheapp's Lab Testing application provides a structured workflow for sample receipt, test assignment, result entry, OOS flagging, and analytical report generation. Every record benefits from automatic, tamper-evident audit trail capture. Electronic signatures on all review and approval steps meet 21 CFR Part 11 requirements. OOS results automatically trigger the investigation workflow in the Out of Specification application, creating a direct and documented link from the flagged result to the investigation record and any associated corrective actions.

The Lab Testing application integrates directly with Cloudtheapp's Batch Records module, so that laboratory release results tie directly to the batch production record that requires them. Quality teams can view the complete picture of a batch — manufacturing record, laboratory testing, OOS investigations, and deviation records — in a single connected platform, rather than assembling it manually from separate systems.

Calibration management connects instrument records to test documentation, and Cloudtheapp's Calibration and Maintenance application tracks calibration schedules, sends due alerts, documents calibration results, and flags instruments with lapsed or failed calibrations before they can be used in a completed test record. Analyst qualification records in the Learning application connect directly to test assignments, enforcing qualification controls at the workflow level.

Because Cloudtheapp is fully validated per FDA Computer Software Assurance guidelines and compliant with ISO 13485, ISO 9001, ISO 22001, and 21 CFR Part 11, the entire laboratory quality system operates within a single validated infrastructure that supports inspection readiness continuously.

Conclusion

Laboratory quality control is among the most heavily scrutinized areas of pharmaceutical and medical device compliance. The regulatory requirements for method validation, instrument qualification, analyst qualification, OOS investigation, and data integrity form a dense, interconnected framework that manual systems and generic software cannot reliably support at scale.

For QC managers and lab directors building or strengthening laboratory quality systems in 2026, the standard is clear: validated, integrated, audit-ready documentation for every analytical activity, accessible to regulators on demand without manual reconstruction.

Cloudtheapp's Lab Testing, OOS, Calibration, and Learning applications give regulated laboratories the validated infrastructure to meet that standard — connected to the broader QMS so that laboratory data flows directly into batch release, CAPA, and annual product review processes without the fragmentation that drives inspection findings.

Request a Demo at cloudtheapp.com to see how Cloudtheapp's laboratory quality control capabilities support your regulated testing environment.

This post created by and appeared first on Cloudtheapp